- Alterity Therapeutics (ATH) has appointed Dr. David Stamler as CEO, effective immediately
- Dr. Stamler has been with the company since June 2017, previously serving as Chief Medical Officer and Senior Vice President Clinical Development
- It’s a great privilege to work towards improving the lives of millions of people suffering from neurodegenerative diseases,” Geoffrey said
- He has significant experience in pharmaceutical development and commercialization
- Dr. Stamler will replace former CEO Geoffrey Kempler, who will continue as Non-Executive Chairman
- Alterity is up 3.23 percent on the market and shares are currently trading at 3.2 cents
